Navigation Links
Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP

SCHAUMBURG, Ill., July 16 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched both ceftriaxone for injection, USP, and cefuroxime for injection, USP, two broad spectrum antibiotics for parenteral administration used to treat bacterial infections. Sagent's ceftriaxone for injection will be available to the U.S. market in 250 mg and 500 mg single dose vials, as well as 1g and 2g single dose vials; cefuroxime for injection will be available in 750 mg and 1.5g single dose vials and in 7.5g pharmacy bulk package vials. According to IMS data, combined 2007 sales for the two antibiotics were $156 million.

"We are excited to introduce these two broad-spectrum antibiotics, incorporating important features unique to Sagent, including enhanced labeling designed to enable rapid and accurate product identification," said Jeffrey M. Yordon, Sagent's chief executive officer, founder, and chairman of the board. "Importantly, this marks our fifth and sixth product launches in the past eight months, in line with our objective of rapidly introducing safe, high- quality products from our pipeline of over 200 products. Sagent is committed to bringing injectables excellence to healthcare providers and patients."

About Ceftriaxone

Ceftriaxone for injection, USP, is a broad spectrum cephalosporin antibiotic used to treat a variety of infections and is the generic equivalent of Roche's Rocephin(R) (ceftriaxone for injection). Ceftriaxone for injection, USP, is indicated for infections of the lower respiratory tract, urinary tract, skin and skin-structure, intra-abdomen, and bones and joints, as well as acute otitis media, uncomplicated gonorrhea, pelvic inflammatory disease, bacterial septicemia and meningitis. Ceftriaxone may also reduce the incidence of postoperative infections is used as a surgical prophylaxis preoperatively.

The most common adverse effects may include nausea, vomiting, stomach pain, headache, dizziness, sweating and vaginal itching or discharge. Less common adverse effects include watery or bloody diarrhea; fever or chills; skin rash; bruising; severe tingling; numbness; pain; muscle weakness; injection site pain, swelling or irritation; heartburn; bloating; and severe upper stomach pain.

About Cefuroxime

Cefuroxime for injection, USP, is a semisynthetic broad spectrum antibiotic agent for parenteral administration used to treat a variety of infections and is the generic equivalent of GlaxoSmithKline's ZINACEF(R) (cefuroxime for injection). Cefuroxime belongs to the cephalosporin family of drugs. Cefuroxime for injection, USP, is indicated for infections of the lower respiratory tract, urinary tract, skin and skin-structure, and bones and joints, as well as septicemia, meningitis, gonorrhea. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefuroxime may be used concomitantly with an aminoglycoside. Cefuroxime may be used prophylactically to prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures that are classified as clean-contaminated or potentially contaminated procedures.

The most common adverse effects may include pain, swelling or redness at the injection site. Less common adverse effects include severe allergic reactions; black or bloody stools; decreased urination; fever, chills, or sore throat; hearing loss; seizures; severe diarrhea, nausea, or vomiting; stomach pain or cramps; unusual bruising or bleeding; vaginal irritation or discharge; vein swelling at the injection site; yellowing of the skin or eyes.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
2. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
4. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by ... known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , ... have embraced this type of racing and several new model aviation pilots have joined ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever that ... muscular dystrophy (DMD) has provided a new lead for ... Hospital, the Broad Institute of MIT and Harvard and ... . Cell, pinpoints a ... "escape" the disease,s effects. The Boston Children,s lab of ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
Breaking Biology News(10 mins):